HomeHealth CareDrugs

Drugs

Health Care

GoodRx Has New Service For ED Meds

Howard Fine - June 23, 2025

Health Care

Anktiva Approved For Additional Treatment

Howard Fine - June 23, 2025

Health Care

FDA Delivers Blow to ImmunityBio

Howard Fine - May 19, 2025

Health Care

NeOnc Sees Share Price Fall Since Going Public

Mark R. Madler - April 14, 2025

Health Care

Acelyrin Sees Stock Price Rise Amid Rights Plan

Mark R. Madler - March 24, 2025

Health Care

ImmunityBio Seeks Drug Approvals

Howard Fine - February 24, 2025

Health Care

Atara Biotherapeutics Sees Its Share Price Fall

Mark R. Madler - January 27, 2025

Health Care

Avita Gets FDA Nod For Device

Howard Fine - January 27, 2025

Health Care

GoodRx Adds Pet Program

Howard Fine - January 27, 2025

Health Care

Amgen Plans To Expand N.C. Campus

Howard Fine - December 30, 2024

Health Care

GoodRx Taps Pharmacy Benefits Exec as CEO

Howard Fine - December 30, 2024

Health Care

ImmunityBio Shares Plunge After Share Offering

Howard Fine - December 16, 2024

Drugs

Arrowhead Pharma Shares See Big Price Jump

Mark R. Madler - December 9, 2024

Health Care

Slew of New Drugs Sends Xencor Shares Soaring

Mark R. Madler - September 23, 2024

Health Care

Atara Biotherapeutics Sees Its Stock Price Rise

Mark R. Madler - September 9, 2024

Health Care

Arrowhead Teeing Up Drug Trials

Howard Fine - September 2, 2024

Health Care

Atara Drug Gets Priority Review

Howard Fine - August 5, 2024

Drugs

GoodRx Launches Price Tracker

Howard Fine - July 8, 2024

Biosciences

Atara Shareholders Approve Reverse Stock Split

Mark R. Madler - June 24, 2024

Drugs

Three Valley Bioscience Firms Reach FDA Milestones

Howard Fine - June 10, 2024

Drugs

GoodRx Cuts New Deal with Kroger; Stock Sees Upgrades

Howard Fine - June 3, 2024

Drugs

ImmunityBio Drug Gets FDA Nod

Howard Fine - April 29, 2024

Drugs

Prolacta Starts Drug Development

Howard Fine - December 11, 2023

Drugs

Arrowhead, Xencor Ink Licensing Deals Potentially Worth $1.5 Billion

Howard Fine - November 29, 2021

Drugs

GoodRx Has New Service For ED Meds

Anktiva Approved For Additional Treatment

FDA Delivers Blow to ImmunityBio

NeOnc Sees Share Price Fall Since Going Public

Acelyrin Sees Stock Price Rise Amid Rights Plan

ImmunityBio Seeks Drug Approvals

Atara Biotherapeutics Sees Its Share Price Fall

Avita Gets FDA Nod For Device

GoodRx Adds Pet Program

Amgen Plans To Expand N.C. Campus

GoodRx Taps Pharmacy Benefits Exec as CEO

ImmunityBio Shares Plunge After Share Offering

Arrowhead Pharma Shares See Big Price Jump

Slew of New Drugs Sends Xencor Shares Soaring

Atara Biotherapeutics Sees Its Stock Price Rise

Arrowhead Teeing Up Drug Trials

Atara Drug Gets Priority Review

GoodRx Launches Price Tracker

Atara Shareholders Approve Reverse Stock Split

Three Valley Bioscience Firms Reach FDA Milestones

GoodRx Cuts New Deal with Kroger; Stock Sees Upgrades

ImmunityBio Drug Gets FDA Nod

Prolacta Starts Drug Development

Arrowhead, Xencor Ink Licensing Deals Potentially Worth $1.5 Billion

Advertise with Us

About Us

Membership Center

Other Journals